Kathleen Claes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7584033/publications.pdf

Version: 2024-02-01

163	9,974	28242 55	43868 91
papers	citations	h-index	g-index

174	174	174	14884
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Atm deficient zebrafish model reveals conservation of the tumour suppressor function and a role in fertility. Genes and Diseases, 2023, 10, 381-384.	1.5	0
2	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
3	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
4	TIM3+ TRBV11-2 T cells and IFNÎ³ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C. Journal of Experimental Medicine, 2022, 219, .	4.2	57
5	Application of an Ultrasensitive NGS-Based Blood Test for the Diagnosis of Early-Stage Lung Cancer: Sensitivity, a Hurdle Still Difficult to Overcome. Cancers, 2022, 14, 2031.	1.7	3
6	Myxoid hepatocellular adenoma, a rare variant of hepatocellular adenoma with distinct imaging features: A case report with immunohistochemical and molecular analysis and literature review. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101478.	0.7	5
7	Timing of blood sampling for butyrylcholinesterase phenotyping in patients with prolonged neuromuscular block after mivacurium or suxamethonium. Acta Anaesthesiologica Scandinavica, 2021, 65, 182-187.	0.7	1
8	Missing heritability in Bloom syndrome: First report of a deep intronic variant leading to pseudoâ€exon activation in the <scp>BLM</scp> gene. Clinical Genetics, 2021, 99, 292-297.	1.0	3
9	Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy. DNA Repair, 2021, 97, 103023.	1.3	2
10	Hereditary Syndromes and Pancreatic Cancer. , 2021, , 29-49.		0
11	Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). Acta Clinica Belgica, 2021, , 1-7.	0.5	9
12	Dealing with Pseudogenes in Molecular Diagnostics in the Next Generation Sequencing Era. Methods in Molecular Biology, 2021, 2324, 363-381.	0.4	1
13	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19
14	Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2021, 6, 1687-1698.	0.4	12
15	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
16	Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer. Scientific Reports, 2021, 11, 12880.	1.6	55
17	Frequency of Participation in External Quality Assessment Programs Focused on Rare Diseases: Belgian Guidelines for Human Genetics Centers. JMIR Medical Informatics, 2021, 9, e27980.	1.3	0
18	Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients. Cancers, 2021, 13, 4430.	1.7	8

#	Article	IF	Citations
19	Somatic mosaics in hereditary tumor predisposition syndromes. European Journal of Medical Genetics, 2021, 64, 104360.	0.7	8
20	Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq. Npj Genomic Medicine, 2021, 6, 95.	1.7	9
21	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
22	Clinical spectrum of individuals with pathogenic N F1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotypeâ€“phenotype study in neurofibromatosis type 1. Human Mutation, 2020, 41, 299-315.	1.1	80
23	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
24	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	0.8	270
25	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
26	Germline Genetic Findings Which May Impact Therapeutic Decisions in Families with a Presumed Predisposition for Hereditary Breast and Ovarian Cancer. Cancers, 2020, 12, 2151.	1.7	5
27	Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome. Journal of Experimental Medicine, 2020, 217, .	4.2	64
28	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
29	Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. European Journal of Human Genetics, 2020, 28, 1387-1393.	1.4	63
30	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
31	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
32	Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma. Genome Medicine, 2020, 12, 35.	3.6	28
33	Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential. Haematologica, 2020, Online ahead of print, 0-0.	1.7	13
34	Chromosomal radiosensitivity of triple negative breast cancer patients. International Journal of Radiation Biology, 2019, 95, 1507-1516.	1.0	2
35	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
36	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88

#	Article	IF	Citations
37	Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report. BMC Cancer, 2019, 19, 567.	1.1	15
38	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
39	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
40	Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotypeâ€“phenotype correlation. Genetics in Medicine, 2019, 21, 867-876.	1.1	62
41	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
42	Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. Familial Cancer, 2019, 18, 281-284.	0.9	17
43	Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI â€“ Current Developments for the Classifi cation of Variants. Klinicka Onkologie, 2019, 32, 51-71.	0.1	5
44	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
45	Thorough in silico and in vitro cDNA analysis of 21 putativeBRCA1andBRCA2splice variants and a complex tandem duplication inBRCA2allowing the identification of activated cryptic splice donor sites inBRCA2exon 11. Human Mutation, 2018, 39, 515-526.	1.1	5
46	Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844â€“848. American Journal of Human Genetics, 2018, 102, 69-87.	2.6	144
47	Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2 -associated hereditary breast and ovarian cancer reveals multiple co-acting second hits. Cancer Letters, 2018, 425, 125-133.	3.2	12
48	The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. Journal of Medical Genetics, 2018, 55, 15-20.	1.5	50
49	Diagnosis of Fanconi Anaemia by ionising radiation- or mitomycin C-induced micronuclei. DNA Repair, 2018, 61, 17-24.	1.3	12
50	Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 232 for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. JCO Precision Oncology, 2018, 2, 1-42.	1.5	19
51	BRCA1 and BRCA2 5â€² noncoding region variants identified in breast cancer patients alter promoter activity and protein binding. Human Mutation, 2018, 39, 2025-2039.	1.1	15
52	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
53	Extreme clustering of type-1 NF1 deletion breakpoints co-locating with G-quadruplex forming sequences. Human Genetics, 2018, 137, 511-520.	1.8	13
54	The Zebrafish as an Emerging Model to Study DNA Damage in Aging, Cancer and Other Diseases. Frontiers in Cell and Developmental Biology, 2018, 6, 178.	1.8	28

#	Article	IF	Citations
55	Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer. Acta Clinica Belgica, 2017, 72, 6-11.	0.5	3
56	BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.4	75
57	Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay. Oncology Reports, 2017, 37, 1379-1386.	1.2	26
58	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
59	Evaluation of relative quantification of alternatively spliced transcripts using droplet digital PCR. Biomolecular Detection and Quantification, 2017, 13, 40-48.	7.0	12
60	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
61	Accurate quantification of homologous recombination in zebrafish: brca2 deficiency as a paradigm. Scientific Reports, 2017, 7, 16518.	1.6	9
62	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
63	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	3.0	242
64	Second hit landscape in BRCA1/2-associated breast cancer. Annals of Oncology, 2017, 28, i9.	0.6	0
65	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
66	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	1.1	10
67	DNA Diagnostics of Hereditary Hearing Loss: A Targeted Resequencing Approach Combined with a Mutation Classification System. Human Mutation, 2016, 37, 812-819.	1.1	76
68	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
69	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
70	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
71	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2016, 157, 319-327.	1.1	26
72	Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation. Breast Cancer Research, 2016, 18, 52.	2.2	25

#	Article	IF	Citations
73	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	2.2	42
74	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
75	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
76	The genetic basis of undiagnosed muscular dystrophies and myopathies. Neurology, 2016, 87, 71-76.	1.5	92
77	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
78	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	3.0	77
79	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
80	High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotypeâ€“Phenotype Correlation. Human Mutation, 2015, 36, 1052-1063.	1.1	143
81	BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. BMC Cancer, 2015, 15, 912.	1.1	41
82	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
83	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34
84	Next Generation Sequencing to Determine the Cystic Fibrosis Mutation Spectrum in Palestinian Population. Disease Markers, 2015, 2015, 1-6.	0.6	11
85	Flexible, Scalable, and Efficient Targeted Resequencing on a Benchtop Sequencer for Variant Detection in Clinical Practice. Human Mutation, 2015, 36, 379-387.	1.1	43
86	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
87	Decoding NF1 Intragenic Copy-Number Variations. American Journal of Human Genetics, 2015, 97, 238-249.	2.6	24
88	Next generation sequencing on patients with LGMD and nonspecific myopathies: Findings associated with ANO5 mutations. Neuromuscular Disorders, 2015, 25, 533-541.	0.3	65
89	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
90	Non Coding RNA Molecules as Potential Biomarkers in Breast Cancer. Advances in Experimental Medicine and Biology, 2015, 867, 263-275.	0.8	32

#	Article	IF	Citations
91	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
92	An abnormally glycosylated isoform of erythropoietin in hemangioblastoma is associated with polycythemia. Clinica Chimica Acta, 2015, 438, 304-306.	0.5	3
93	Focus on 16p13.3 Locus in Colon Cancer. PLoS ONE, 2015, 10, e0131421.	1.1	11
94	Jaffeâ€“Campanacci syndrome, revisited: detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations, or a distinct disorder. Genetics in Medicine, 2014, 16, 448-459.	1.1	33
95	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
96	Palindrome-Mediated and Replication-Dependent Pathogenic Structural Rearrangements within theNF1Gene. Human Mutation, 2014, 35, 891-898.	1.1	13
97	Breast-Cancer Risk in Families With Mutations in PALB2. Obstetrical and Gynecological Survey, 2014, 69, 659-660.	0.2	1
98	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
99	Breast-Cancer Risk in Families with Mutations in PALB2. New England Journal of Medicine, 2014, 371, 497-506.	13.9	745
100	Mate pair sequencing for the detection of chromosomal aberrations in patients with intellectual disability and congenital malformations. European Journal of Human Genetics, 2014, 22, 652-659.	1.4	32
101	Comparison of mRNA Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing. Clinical Chemistry, 2014, 60, 341-352.	1.5	95
102	SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints. Genome Biology, 2014, 15, R80.	13.9	63
103	Dealing with Pseudogenes in Molecular Diagnostics in the Next-Generation Sequencing Era. Methods in Molecular Biology, 2014, 1167, 303-315.	0.4	29
104	Variant Ataxia Telangiectasia: Clinical and Molecular Findings and Evaluation of Radiosensitive Phenotypes in a Patient and Relatives. NeuroMolecular Medicine, 2013, 15, 447-457.	1.8	29
105	A sensitive and specific diagnostic test for hearing loss using a microdroplet PCRâ€based approach and next generation sequencing. American Journal of Medical Genetics, Part A, 2013, 161, 145-152.	0.7	61
106	Analysis of the Novel Fanconi Anemia GeneSLX4/FANCPin Familial Breast Cancer Cases. Human Mutation, 2013, 34, 70-73.	1.1	21
107	Lhermitte-Duclos disease with obstructive hydrocephalus: An illustrative case treated with endoscopic ventriculo-cisternostomy. Revue Neurologique, 2013, 169, 917-919.	0.6	2
108	Radiation-induced myosin IIA expression stimulates collagen type I matrix reorganization. Radiotherapy and Oncology, 2013, 108, 162-167.	0.3	7

#	Article	IF	Citations
109	A multicentric, international matched pair analysis of body composition in peritoneal dialysis versus haemodialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 2620-2628.	0.4	61
110	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
111	Multiple orbital neurofibromas, painful peripheral nerve tumors, distinctive face and marfanoid habitus: a new syndrome. European Journal of Human Genetics, 2012, 20, 618-625.	1.4	9
112	Questioning the Pathogenic Role of the GLA p.Ala143Thr â€œMutationâ€•in Fabry Disease: Implications for Screening Studies and ERT. JIMD Reports, 2012, 8, 101-108.	0.7	44
113	Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. British Journal of Cancer, 2012, 106, 1460-1463.	2.9	43
114	Identification of recurrent type-2NF1microdeletions reveals a mitotic nonallelic homologous recombination hotspot underlying a human genomic disorder. Human Mutation, 2012, 33, 1599-1609.	1.1	26
115	Polymorphisms in the lectin pathway genes as a possible cause of early chronic Pseudomonas aeruginosa colonization in cystic fibrosis patients. Human Immunology, 2012, 73, 1175-1183.	1.2	47
116	Midline nasal dermoid sinus cyst in basal cell naevus syndrome (BCNS or Gorlin syndrome): A case report and review. International Journal of Pediatric Otorhinolaryngology Extra, 2012, 7, 119-121.	0.1	0
117	Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing. Breast Cancer Research and Treatment, 2012, 133, 393-398.	1.1	23
118	Mitotic recombination of chromosome arm 17q as a cause of loss of heterozygosity of NF1 in neurofibromatosis type 1â€associated glomus tumors. Genes Chromosomes and Cancer, 2012, 51, 429-437.	1.5	27
119	Characterization of the nonallelic homologous recombination hotspot PRS3 associated with type-3NF1deletions. Human Mutation, 2012, 33, 372-383.	1.1	28
120	Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing. Breast Cancer Research and Treatment, 2012, 132, 87-95.	1.1	29
121	Prostate cancer in Cowden syndrome: somatic loss and germline mutation of the PTEN gene. Cancer Genetics, 2011, 204, 224-225.	0.2	8
122	Fluid Status in Peritoneal Dialysis Patients: The European Body Composition Monitoring (EuroBCM) Study Cohort. PLoS ONE, 2011, 6, e17148.	1.1	216
123	Objective assessment of nasality in flemish adults with neurofibromatosis type 1. American Journal of Medical Genetics, Part A, 2011, 155, 2974-2981.	0.7	2
124	Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRCA2: opportunities, challenges, and limitations. Human Mutation, 2011, 32, 335-344.	1.1	58
125	A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Annals of the Rheumatic Diseases, 2011, 70, 638-641.	0.5	63
126	Combined effect of polymorphisms in Rad51 and Xrcc3 on breast cancer risk and chromosomal radiosensitivity. Molecular Medicine Reports, 2011, 4, 901-12.	1.1	27

#	Article	IF	Citations
127	Practical Tools to Implement Massive Parallel Pyrosequencing of PCR Products in Next Generation Molecular Diagnostics. PLoS ONE, 2011, 6, e25531.	1.1	40
128	The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP). Acta Gastro-Enterologica Belgica, 2011, 74, 421-6.	0.4	11
129	Leiden open variation database of the MUTYH gene. Human Mutation, 2010, 31, 1205-1215.	1.1	72
130	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.4	169
131	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2010, 19, 2886-2897.	1.4	60
132	<i>IRF6</i> Screening of Syndromic and a priori Non-Syndromic Cleft Lip and Palate Patients: Identification of a New Type of Minor VWS Sign. Molecular Syndromology, 2010, 1, 67-74.	0.3	28
133	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	1.4	99
134	Glomus Tumors in Neurofibromatosis Type 1: Genetic, Functional, and Clinical Evidence of a Novel Association. Cancer Research, 2009, 69, 7393-7401.	0.4	122
135	Functional redundancy of exon 12 ofBRCA2revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant. Human Mutation, 2009, 30, 1543-1550.	1.1	30
136	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	2.9	15
137	Acute Normal Tissue Reactions in Head-and-Neck Cancer Patients Treated With IMRT: Influence of Dose and Association With Genetic Polymorphisms in DNA DSB Repair Genes. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1187-1195.	0.4	113
138	Genotyping of Frequent BRCA1/2 SNPs with Unlabeled Probes. Journal of Molecular Diagnostics, 2009, 11, 415-419.	1.2	21
139	Polymorphisms in nonhomologous endâ€joining genes associated with breast cancer risk and chromosomal radiosensitivity. Genes Chromosomes and Cancer, 2008, 47, 137-148.	1.5	51
140	Spectrum and characterisation of BRCA1 and BRCA2deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. BMC Cancer, 2008, 8, 140.	1.1	64
141	Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population. European Journal of Cancer, 2008, 44, 2288-2295.	1.3	19
142	Rapid and Sensitive Detection of BRCA1/2 Mutations in a Diagnostic Setting: Comparison of Two High-Resolution Melting Platforms. Clinical Chemistry, 2008, 54, 982-989.	1.5	65
143	Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients. Nephrology Dialysis Transplantation, 2008, 23, 4044-4048.	0.4	17
144	Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population. Nephrology Dialysis Transplantation, 2007, 23, 294-300.	0.4	31

#	Article	IF	Citations
145	Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2007, 631, 101-110.	0.9	194
146	Benign retroperitoneal schwannoma presenting as colitis: A case report. World Journal of Gastroenterology, 2007, 13, 5521.	1.4	29
147	TGFÎ²1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1240-1248.	0.4	57
148	Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients. Genes Chromosomes and Cancer, 2006, 45, 265-276.	1.5	129
149	Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: Association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1140-1149.	0.4	114
150	Rapid detection of VHL exon deletions using real-time quantitative PCR. Laboratory Investigation, 2005, 85, 24-33.	1.7	102
151	Chromosomal radiosensitivity of breast cancer with a mutation. Cancer Genetics and Cytogenetics, 2005, 163, 106-112.	1.0	13
152	BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. British Journal of Cancer, 2004, 90, 1244-1251.	2.9	46
153	THE RATE OF GASTRIC EMPTYING DETERMINES THE TIMING BUT NOT THE EXTENT OF ORAL TACROLIMUS ABSORPTION: SIMULTANEOUS MEASUREMENT OF DRUG EXPOSURE AND GASTRIC EMPTYING BY CARBON-14-OCTANOIC ACID BREATH TEST IN STABLE RENAL ALLOGRAFT RECIPIENTS. Drug Metabolism and Disposition, 2004, 32, 1421-1425.	1.7	28
154	Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers. International Journal of Radiation Biology, 2004, 80, 745-756.	1.0	64
155	Differentiating pathogenic mutations from polymorphic alterations in the splice sites ofBRCA1 andBRCA2. Genes Chromosomes and Cancer, 2003, 37, 314-320.	1.5	78
156	Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5â€² end of the BRCA1 gene. Oncogene, 2002, 21, 4171-4175.	2.6	35
157	Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition. British Journal of Cancer, 2002, 87, 1379-1385.	2.9	122
158	A Homozygous MSH6 Mutation in a Child with CafÃ©-au-Lait Spots, Oligodendroglioma and Rectal Cancer. Familial Cancer, 2002, 3, 123-127.	0.9	74
159	The Exon 13 Duplication in the BRCA1 Gene Is a Founder Mutation Present in Geographically Diverse Populations. American Journal of Human Genetics, 2000, 67, 207-212.	2.6	100
160	Mutation Analysis of the BRCA1 and BRCA2 Genes in the Belgian Patient Population and Identification of a Belgian Founder Mutation BRCA1 IVS5+3A>G. Disease Markers, 1999, 15, 69-73.	0.6	27
161	Genetic Counselling and Testing for Hereditary Breast and Ovarian Cancer: The Gent(le) Approach. Disease Markers, 1999, 15, 191-195.	0.6	5
162	Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 Flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. , 1999, 13, 256-256.		22

#	Article	IF	Citations
163	Decreased DNA doubleâ€'strand break repair and enhanced chromosomal radiosensitivity in irradiated nonâ€'tumorigenic human breast epithelial cells with a partial BRCA1 or BRCA2 knockdown. World Academy of Sciences Journal, 0, , .	0.4	0